Cargando…

Clinical usefulness of mepolizumab in severe eosinophilic asthma

Asthma is a chronic inflammatory disorder of the airways with variable clinical severity from very mild and occasional symptoms to recurrent critical exacerbations, at risk of fatal or near-fatal outcome, in a small percentage of patients. Within the different inflammatory cascades involved in asthm...

Descripción completa

Detalles Bibliográficos
Autores principales:	Menzella, Francesco, Lusuardi, Mirco, Montanari, Gloria, Galeone, Carla, Facciolongo, Nicola, Zucchi, Luigi
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove Medical Press 2016
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4907717/ https://www.ncbi.nlm.nih.gov/pubmed/27354806 http://dx.doi.org/10.2147/TCRM.S86299

Ejemplares similares

The clinical profile of benralizumab in the management of severe eosinophilic asthma
por: Menzella, Francesco, et al.
Publicado: (2016)

Profile of anti-IL-5 mAb mepolizumab in the treatment of severe refractory asthma and hypereosinophilic diseases
por: Menzella, Francesco, et al.
Publicado: (2015)

Near-fatal asthma responsive to mepolizumab after failure of omalizumab and bronchial thermoplasty
por: Menzella, Francesco, et al.
Publicado: (2017)

Tailored therapy for severe asthma
por: Menzella, Francesco, et al.
Publicado: (2015)

Heat-induced necrosis after bronchial thermoplasty: a new concern?
por: Menzella, Francesco, et al.
Publicado: (2018)

Bronchial thermoplasty and the role of airway smooth muscle: are we on the right direction?
por: Menzella, Francesco, et al.
Publicado: (2017)

Successful treatment with benralizumab in a patient with eosinophilic granulomatosis with polyangiitis refractory to mepolizumab
por: Menzella, Francesco, et al.
Publicado: (2021)

Acute respiratory failure as presentation of late-onset Pompe disease complicating the diagnostic process as a labyrinth: a case report
por: Menzella, Francesco, et al.
Publicado: (2018)

A case of chronic eosinophilic pneumonia in a patient treated with dupilumab
por: Menzella, Francesco, et al.
Publicado: (2019)

Recurrent lung atelectasis from fibrin plugs as a very early complication of bronchial thermoplasty: a case report
por: Facciolongo, Nicola, et al.
Publicado: (2015)

Innovative treatments for severe refractory asthma: how to choose the right option for the right patient?
por: Menzella, Francesco, et al.
Publicado: (2017)

Economic impact of mepolizumab in uncontrolled severe eosinophilic asthma, in real life()
por: Bagnasco, Diego, et al.
Publicado: (2021)

Immunological Aspects Related to Viral Infections in Severe Asthma and the Role of Omalizumab
por: Menzella, Francesco, et al.
Publicado: (2021)

Long-term benefits of omalizumab in a patient with severe non-allergic asthma
por: Menzella, Francesco, et al.
Publicado: (2011)

Eosinophil‐derived neurotoxin and clinical outcomes with mepolizumab in severe eosinophilic asthma
por: Howarth, Peter, et al.
Publicado: (2020)

Precision Medicine in Targeted Therapies for Severe Asthma: Is There Any Place for “Omics” Technology?
por: Galeone, Carla, et al.
Publicado: (2018)

Eosinophilic infiltrate in a patient with severe Legionella pneumonia as a levofloxacin-related complication: a case report
por: Facciolongo, Nicola, et al.
Publicado: (2010)

Patient profiles and clinical utility of mepolizumab in severe eosinophilic asthma
por: Haldar, Pranabashis
Publicado: (2017)

Efficacy of add-on mepolizumab in adolescents with severe eosinophilic asthma
por: Yancey, Steven W., et al.
Publicado: (2019)

Anti-IL5 Therapies for Severe Eosinophilic Asthma: Literature Review and Practical Insights
por: Menzella, Francesco, et al.
Publicado: (2020)

The clinical benefit of mepolizumab replacing omalizumab in uncontrolled severe eosinophilic asthma
por: Chapman, Kenneth R., et al.
Publicado: (2019)

Towards precision medicine: The application of omics technologies in asthma management
por: Scelfo, Chiara, et al.
Publicado: (2018)

Efficacy of mepolizumab for patients with severe asthma and eosinophilic chronic rhinosinusitis
por: Numata, Takanori, et al.
Publicado: (2019)

Clinical and economic consequences of switching from omalizumab to mepolizumab in uncontrolled severe eosinophilic asthma
por: Carpagnano, Giovanna Elisiana, et al.
Publicado: (2021)

The pharmacoeconomics of the state-of-the-art drug treatments for asthma: a systematic review
por: Menzella, Francesco, et al.
Publicado: (2021)

Effectiveness and safety of mepolizumab in severe refractory eosinophilic asthma: results in clinical practice
por: Montero-Pérez, Olalla, et al.
Publicado: (2019)

Blood Eosinophil Depletion with Mepolizumab, Benralizumab, and Prednisolone in Eosinophilic Asthma
por: Moran, Angela M., et al.
Publicado: (2020)

Real-world characteristics of “super-responders” to mepolizumab and benralizumab in severe eosinophilic asthma and eosinophilic granulomatosis with polyangiitis
por: Portacci, Andrea, et al.
Publicado: (2023)

Update: Mepolizumab treatment in patients with severe eosinophilic asthma and prior omalizumab use
por: Albers, Frank C., et al.
Publicado: (2019)

Response to Mepolizumab Treatment in Patients with Severe Eosinophilic Asthma and Atopic Phenotypes
por: Prazma, Charlene M, et al.
Publicado: (2021)

Bronchial thermoplasty in severe asthma: a real-world study on efficacy and gene profiling
por: Facciolongo, Nicola, et al.
Publicado: (2022)

Targeting eosinophils: severe asthma and beyond
por: Caminati, Marco, et al.
Publicado: (2019)

A Real-World Evaluation of Clinical Outcomes of Biologicals and Bronchial Thermoplasty for Severe Refractory Asthma (BIOTERM)
por: Menzella, Francesco, et al.
Publicado: (2021)

Treatment response with mepolizumab in severe eosinophilic asthma patients with previous omalizumab treatment
por: Magnan, A., et al.
Publicado: (2016)

Mepolizumab in the management of severe eosinophilic asthma in adults: current evidence and practical experience
por: Varricchi, Gilda, et al.
Publicado: (2016)

Eosinophils depletion therapy for severe asthma management following favorable response to mepolizumab
por: Matsuno, Osamu, et al.
Publicado: (2019)

Mepolizumab in the management of severe eosinophilic asthma in adults: current evidence and practical experience
por: Emma, Rosalia, et al.
Publicado: (2018)

Fungal sensitization and its relationship to mepolizumab response in patients with severe eosinophilic asthma
por: Wardlaw, Andrew, et al.
Publicado: (2020)

Subcutaneous mepolizumab in children aged 6 to 11 years with severe eosinophilic asthma
por: Gupta, Atul, et al.
Publicado: (2019)

Remission outcomes in severe eosinophilic asthma with mepolizumab therapy: Analysis of the REDES study
por: Pavord, Ian, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_08ntdvv0767t25ob6033kuccao